Incyte (INCY) Cash from Restructuring (2010 - 2011)
Incyte (INCY) reported Cash from Restructuring of -$108000.0 for Q4 2011, down 640.0% on a YoY basis from $20000.0 in Q4 2010, and down 183.72% quarter-over-quarter from $129000.0 in Q2 2011.
Incyte (INCY) Cash from Restructuring (2010 - 2011) Analysis & Trends
Incyte has reported Cash from Restructuring for 2 years, with the latest figure at -$108000.0 in Q4 2011.
- For the quarter ending Q4 2011, Cash from Restructuring fell 640.0% year-over-year to -$108000.0; the trailing twelve-month figure through Dec 2011 stood at -$88000.0 (up 76.78% YoY), and the FY2011 full-year result was -$88000.0, up 76.78% from the prior year.
- Cash from Restructuring for Q4 2011 stood at -$108000.0, down from $129000.0 in the prior quarter.
- The five-year high for Cash from Restructuring was $129000.0 in Q2 2011, with the low at -$145000.0 in Q2 2010.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Incyte | 19.62 Bn | 15.60 Bn | 1.17 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2011 | -108,000.00 |
| Jun 30, 2011 | 129,000.00 |
| Mar 31, 2011 | -109,000.00 |
| Dec 31, 2010 | 20,000.00 |
| Sep 30, 2010 | -139,000.00 |
| Jun 30, 2010 | -145,000.00 |
| Mar 31, 2010 | -115,000.00 |